Therapeutic Drug Monitoring for 5‑Fluorouracil
Customize your policy alerts
Sign up for medical mutual - ohio Policy AHS - M2067 alerts
Get alerted when Policy AHS - M2067 changes without checking for updates manually.
Monitor payer policy activity
Defines coverage stance for therapeutic drug monitoring to guide dosing of intravenous 5-fluorouracil (5-FU) for individuals receiving 5-FU chemotherapy and lists tests that do not meet coverage. Affects providers requesting TDM services under Medical Mutual - Ohio benefits.
No material clinical or coverage changes in this revision.
Coverage Criteria for 5‑FU Therapeutic Drug Monitoring
Covered Indication — 5-FU TDM
Covered when ALL of the following are met:
Policy statement: TDM to aid dose adjustment meets coverage criteria.
Target AUC range referenced in scientific background and policy.
Guideline-aligned recommendation to assess DPYD/DPD status to inform dosing and TDM interpretation.
Coverage supports use of AUC measurement to guide dose titration and clinical monitoring.
Policy covers infusional 5-FU regimens where AUC measurement and dose optimization are applied.
Not covered tests
Not covered:
Listed explicitly as not meeting coverage criteria due to lack of published scientific literature.
Listed explicitly as not meeting coverage criteria due to lack of published scientific literature.
The policy explicitly excludes certain approaches to assessing fluoropyrimidine exposure or DPD activity. Specifically, uracil breath tests and dihydrouracil/uracil ratio testing of plasma, serum, or urine do not meet coverage criteria for managing dose adjustment of 5‑fluorouracil due to insufficient published scientific literature demonstrating they are required and beneficial for diagnosis or treatment.
Patients known to have complete DPD (dihydropyrimidine dehydrogenase) deficiency should not receive 5‑fluorouracil or related fluoropyrimidine substances. The European Medicines Agency (PRAC) concluded that benefit–risk is negative in patients with complete DPD deficiency and that these medicinal products are contraindicated in this population; patients with partial deficiency require adjusted starting doses.
A literature review was completed as part of the policy update and the review did not necessitate any modification to the existing coverage criteria for therapeutic drug monitoring of 5‑fluorouracil; prior authorization and coverage requirements therefore remain unchanged.
Although this policy supports Therapeutic Drug Monitoring (TDM) to guide AUC‑based dose adjustment for patients receiving intravenous 5‑FU when documented genotype/phenotype assessment and AUC measurements are used, not all guideline sources uniformly endorse routine TDM. The NCCN guidelines do not address TDM for 5‑FU in disease‑specific guidance and include no AUC‑based dosing recommendations for 5‑FU, and the NICE review states the My5‑FU assay shows promise but should be recommended only for research purposes. These guideline positions are reflected in the policy’s mixed stance: TDM for 5‑FU meets coverage criteria when used in an evidence‑based, guideline‑aligned manner with appropriate documentation, but some assays and contexts remain investigational or limited in scope per external guidance.
Regimens Covered with AUC-guided TDM
| Regimen / Setting | Indication for AUC-guided dose adjustment |
|---|---|
| Continuous intravenous 5‑fluorouracil (5‑FU) infusion (single‑agent or combination regimens) | Dose adjustment when therapeutic drug monitoring (AUC) shows exposure outside target range (target AUC 20–30 mg×h/L) to reduce toxicity and optimize efficacy; used when clinician requests TDM to aid titration. |
| Standard BSA‑based 5‑FU infusion regimens where interpatient variability is suspected or prior toxicity occurred | Post‑therapy or between‑cycle AUC measurement to guide upward or downward dose titration to achieve target AUC 20–30 mg×h/L, consistent with trial and guideline practice. |
| Capecitabine with conversion to equivalent 5‑FU exposure (when managed clinically as part of TDM protocol) | When capecitabine exposure is being monitored via equivalent 5‑FU AUC calculations and dose optimization is required to reach target AUC 20–30 mg×h/L. |
| Example regimen / scenario | Notes / examples of measurement or conversion |
|---|---|
| Continuous‑infusion 5‑FU (eg, regimens used in colorectal or head‑and‑neck cancer) | AUC (mg×h/L) measured from serial plasma sampling each cycle; adjust subsequent cycle dose per TDM protocol to reach 20–30 mg×h/L (IATDMCT guidance; clinical trials target range). |
| 5‑FU containing combination regimens (eg, FOLFOX, FOLFIRI) using continuous infusion component | Monitor infusion 5‑FU AUC and titrate infusion dose within the combination regimen to achieve target exposure and minimize grade 3–4 toxicity, as supported by randomized and observational studies. |
| Patients initially dosed by BSA who demonstrate subtherapeutic or supratherapeutic exposure | Apply PK‑guided adjustments: studies (Wilhelm; PREDICT‑5FU) show many patients miss target AUC with BSA dosing and that TDM improves proportion achieving 20–30 mg×h/L after adjustment. |
| Capecitabine regimens where clinicians convert oral dosing to expected 5‑FU exposure for monitoring | Serial sampling and calculated equivalent 5‑FU AUC used to inform capecitabine dose modifications under a TDM protocol (PREDICT‑5FU feasibility data). |
Procedure and Assay Codes
| No codes listed |
| S3722 | Dose optimization by area under the curve (AUC) analysis, for infusional 5-fluorouracil |
| 80299 | Quantitation of therapeutic drug, not elsewhere specified |
| 82542 | Column chromatography, includes mass spectrometry, if performed (eg, HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen |
| 83789 | Mass spectrometry and tandem mass spectrometry (eg, MS, MS/MS, MALDI, MS-TOF, QTOF), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen |
Provider Actions, Documentation & Authorization Guidance
TDM for 5‑FU meets coverage when used to aid dose adjustment
Therapeutic drug monitoring (TDM) for individuals undergoing 5‑fluorouracil (5‑FU) chemotherapy meets coverage criteria when requested to aid in dose adjustment.
Prior authorization requirements remain unchanged
The policy review updated background and references but did not change prior authorization requirements; existing prior authorization processes remain in effect.
Sequence genotyping/phenotyping before treatment and use TDM for titration
Guidance recommends performing DPYD genotyping or DPD phenotyping before initiating fluoropyrimidine therapy and using therapeutic drug monitoring (AUC-based TDM) for dose titration and follow-up when genotype-guided dose reductions are applied or when titration is required.
- Genotype/phenotype assessment (DPYD or uracil/uracilemia) is recommended before FP-based chemotherapy (EMA/CPIC/STP-PT guidance).
- Follow-up AUC-based TDM is recommended to titrate doses after genotype-guided reductions or when dose escalation is considered.
Clinical guidance sources inform testing sequence
Clinical guidance documents (CPIC, SFPT/GPCO-Unicancer, STP-PT and EMA assessments) inform recommended sequencing of DPD genotyping/phenotyping prior to fluoropyrimidine initiation and the use of TDM for dose optimization thereafter.
- CPIC 2017 guidance recommends genotype-informed dosing with follow-up TDM when dose reductions are applied.
- SFPT/GPCO-Unicancer and STP-PT recommend implementation of 5‑FU TDM to ensure adequate exposure.
- EMA recommends DPD testing before initiation of FP-based chemotherapy.
Document clinical indication: undergoing 5‑FU chemotherapy and TDM for dose adjustment
Document that the individual is currently receiving 5‑fluorouracil chemotherapy and that TDM is being requested specifically to aid dose adjustment.
- Include statement of active 5‑FU chemotherapy in the clinical indication.
- Explain that the purpose of the TDM request is to guide dose adjustment.
Include genotype/phenotype results and AUC measures in documentation
Include DPYD genotype results or DPD phenotype (uracil/uracilemia) results and any available therapeutic drug monitoring AUC measurements in authorization documentation.
- Provide DPYD genotype or DPD phenotype (uracil) test results, if performed.
- Include AUC values from TDM and note how results will be used to adjust dosing.
Supportive evidence to include with requests
Attach relevant supportive evidence when submitting TDM authorization requests, such as NICE reviews, CPIC guidance, SFPT/GPCO-Unicancer/STP-PT recommendations, EMA assessments, and applicable FDA product labeling.
- NICE review of My5‑FU assay
- CPIC 2017 DPYD guideline
- SFPT/GPCO-Unicancer and STP-PT recommendations
- EMA PRAC assessment on fluorouracil
- FDA product labeling where applicable
Uracil breath tests and dihydrouracil/uracil ratio testing are not covered
Requests for uracil breath tests and dihydrouracil/uracil ratio testing for managing 5‑FU dose adjustment do not meet coverage criteria and may be denied.
- Uracil breath tests are explicitly listed as not meeting coverage.
- Dihydrouracil/uracil ratio testing of plasma, serum, or urine is explicitly listed as not meeting coverage.
5‑FU contraindicated in known complete DPD deficiency (EMA)
Use of 5‑fluorouracil (and related substances) is contraindicated in patients with known complete DPD deficiency per the EMA assessment; such cases should not be authorized for 5‑FU therapy.
- EMA concluded products are contra‑indicated in patients with complete DPD deficiency.
- Patients with partial DPD deficiency should be treated with adjusted starting doses per EMA.
No changes to authorization criteria after literature review
The literature review and policy update did not require changes to the coverage or authorization criteria; continue to apply existing authorization rules.
Biomarker and Phenotype Requirements for Testing
Definitions
Background and Evidence Summary
5‑Fluorouracil (5‑FU) is a commonly used intravenous chemotherapeutic agent with a narrow therapeutic index. Conventional body surface area (BSA) dosing shows substantial interpatient variability in systemic exposure, which can lead to underexposure or excessive toxicity. Therapeutic drug monitoring (TDM) using area‑under‑the‑curve (AUC)–guided dosing is intended to optimize systemic exposure; the policy references a target exposure range of 20–30 mg×h/L as the goal for AUC‑based 5‑FU dose individualization to improve efficacy and reduce high‑grade toxicity.
Supporting guideline and evidence summaries note divergent positions: some specialty groups and pharmacology consortia support genotype/phenotype assessment and implementation of AUC‑based TDM in appropriate clinical settings, while major guideline bodies vary in their endorsements. Specifically, the policy cites that NCCN does not include TDM for 5‑FU in its disease‑specific guidelines, and NICE recommends the My5‑FU assay only for research purposes. These contextual statements were used to align the coverage stance with the current guideline landscape.
Revision History
Reviewed and updated background, guidelines, and evidence-based scientific references; literature review did not necessitate modifications to coverage criteria.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.